Features

New to This Edition

• Chapter 9,  Cannabis,  features: new material on the legal status of marijuana, new coverage of marijuana usage, new research on Cannabidiol and it’s pharmokinetics; new research on the use of marijuana to treat Alzheimers, PTSD,  and Epilepsy.   New coverage of pharmacological, physiological, and psychoactive effects  of synthetic marijuana including its toxicity.
• Chapter 10, Opioids features: New section Opioid Misuse and Abuse presents the scope of the current opioid epidemic in the US; New discussions of the recent increase in heroin use;  new formulations of hydrocordone and oximorphone, and new research into methadone use and effects,  New section on the Use of Buprenorphine for the Treatment of Opioid Dependence. New research on and new formulations of drugs used to treat opioid overdose:  Naltrexone, Nalmefene, and Naloxone. New discussion of Illicit Opioids of Abuse include coverage of Synthetic Fentanyl Derivatives  and New research on the use of Kratom, an herbal drug with opiate effects.
• Chapter 5 Ethyl Alcohol and the Inhalants of Abuse includes new research on the effect of persistent alcohol use in adolescence; pharmacotherapies that maintain abstinence from alcohol and prevent relapse including opioid antagonists and ketamine; and a new appendix on alcohol use disorder.
• Chapter 11, Antipsychotic Drugs s has been completely revised to include new research on the causes of schizophrenia, new research of the efficacy of  antipsychotics to treat  dementia, parkinsons, bipolar, OCD, PTSD, new research on the efficacy and toxicity of first generation antipsychotics v. Second generation anti psychotic, and discussion new antipsychotics in the pipeline.
• Chapter 6 Caffeine and Nicotine includes New research on how nicotine effects the brain, a new section smoking and mental health;  new research on effectiveness of Chantix and Buboprion for nicotine dependence, a new material on the effects of e-cigarettes and vapor products, their use in smoking cessation, and  their use among young people,
• Chapter 7, Cocaine, the Amphetamines, and Other Psychostimulants, includes new research on the effects of bath salts, new data on their usage, and discussion of new bath salt formulations.
• Chapter 8, Psychadelic Drugs includes new research on MDMA for treatment of PTSD, Psychsiblin for treatment of depression and end-of-life anxiety, and ayahuasca  to treat psychiatric disorders
• Chapter 12 Antidepressant drugs includes,  new research on the use of ketamine for the treatment of depression; New research on effectiveness of antidepressants; The use of genetic testing to predict effectiveness of  antidepressant treatment; revised discussion of treatment resistant depression and drugs used to augment antidepressants.
• Chapter 14, Drugs Used to Treatment Bipolar disorders features new research on the efficacy and mechanism of action of treatment for bipolar disorder as well the pathophysiology of bipolar disorder.
• Chapter 15, Child and Adolescent Psychopharmacology features New research on the effects of cannabis, alcohol, nicotine, stimulants, and antidepressant use during pregnancy. New material regarding the use of illicit drugs during teenage years, including the effects of persistent marijuana, alcohol, and stimulant use in the teen years. New research on the treatment of psychiatric disorders in adolescence.
• Chapter 16 Geriatric Psychopharmacology includes material on the treatment of Dementia, Alzheimers, and Parkinsons disease as well as use of antipsychotics in elderly patients.
• Chapter 17 Challenging Times for Mental Illness includes, updated discussion on the epidemiology of mental illness. New discussion of updated ways of studying mental illness. New discussion of the resurgence of non-pharmaceutical treatment of mental illness.